By Nikolaj Skydsgaard COPENHAGEN (Reuters) – Novo Nordisk's experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent, according to results released on Friday, paving the way for a new and bigger study on the drug's benefits. Semaglutide is the third diabetes drug to show such heart benefits, after Novo's Victoza injectable and Eli Lilly and Boehringer Ingelheim's Jardiance pill. Novo is already planning a longer study of semaglutide similar to Leader, specifically aimed toward getting a label-claim, Novo's chief science officer Mads Krogsgaard told Reuters, referring to Novo's 9,000 patient Victoza study, which lasted five years.
Originally posted here:
Novo plans larger study after encouraging semaglutide results
